Primary Sclerosing Cholangitis Market

1. Primary Sclerosing Cholangitis Market Growth Anticipated: Primary Sclerosing Cholangitis Set for Robust Expansion up to 2032, Major Players Include HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics In the market landscape of Primary Sclerosing Cholangitis, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled “Primary Sclerosing Cholangitis Market Insights, Epidemiology and Market Forecast, 2032” from DelveInsight. Noteworthy advancements are projected, fueled not only by existing approved therapies but also by the introduction of emerging treatments slated for launch between 2023 and 2032, incremental increase in incidence is reported to impact the market significantly. The report sheds light on Primary Sclerosing Cholangitis current treatment practices, upcoming drugs in the Primary Sclerosing Cholangitis pipeline, market shares of individual therapies, and the anticipated trajectory of the Primary Sclerosing Cholangitis market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan). Driving Forces Behind the Primary Sclerosing Cholangitis Market Growth The overall market of Primary Sclerosing Cholangitis (PSC) is expected to boost due to the expected launch of emerging therapy in the forecasted period (2023–2032). Discover the Anticipated Evolution and Growth of the Market @ Primary Sclerosing Cholangitis Therapeutics Market Forecast Therapeutic Advancements and Emerging Treatments: ● Primary Sclerosing Cholangitis Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry. ● Primary Sclerosing Cholangitis Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Primary Sclerosing Cholangitis.

2. Therapies such as HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and others are driving the Primary Sclerosing Cholangitis market. Primary Sclerosing Cholangitis Epidemiological Trends and Patient Demographics: - According to DelveInsight analysis, in the US the diagnosed prevalence of Primary Sclerosing Cholangitis is higher in males than females. According to DelveInsight analysis, in EU4 and the UK, the symptomatic cases of Primary Sclerosing Cholangitis are higher than asymptomatic cases. - Report Features Details Geography Coverage 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Study Period 2019-2032 Market Size ~USD 113 million in 2022 Key Companies HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, and others. The market size of primary sclerosing cholangitis (PSC) is anticipated to increase during the study period, 2019–2032. The expected launch of therapies will lead to change in market dynamics during the forecast period (2023-2032). Leading Primary Sclerosing Cholangitis Companies and Emerging Drugs: Pioneering companies such as HighTide Biopharma, Dr. Falk Pharma, Albireo, Pliant Therapeutics, among others, are actively developing novel drugs for potential entry into the Primary Sclerosing Cholangitis market. Primary Sclerosing Cholangitis Therapeutic Landscape: Key therapies identified for Primary Sclerosing Cholangitis treatment include HTD1801, Norursodeoxycholic acid, A3907, PLN-74809 (bexotegrast), and more. Primary Sclerosing Cholangitis Overview:

3. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation, scarring (fibrosis), and narrowing of the bile ducts inside and outside the liver. Over time, this progressive condition can lead to liver damage, cirrhosis, and complications such as liver failure, bile duct infections (cholangitis), and an increased risk of bile duct and liver cancer (cholangiocarcinoma). Cause: The exact cause of PSC is not fully understood. It is believed to involve an autoimmune component, where the body's immune system mistakenly attacks the bile ducts, leading to inflammation and scarring. PSC is also associated with other autoimmune conditions such as inflammatory bowel disease (IBD), particularly ulcerative colitis. Symptoms: Many individuals with PSC initially have no symptoms (asymptomatic), but as the disease progresses, they may experience fatigue, itching (pruritus), jaundice (yellowing of the skin and eyes), abdominal pain, fever, weight loss, and complications related to bile duct obstruction or liver damage. Diagnosis: Diagnosis of PSC involves a combination of blood tests, imaging studies (such as MRI or ERCP), and sometimes a liver biopsy to assess liver tissue for characteristic changes. Additionally, colonoscopy or other tests may be performed to evaluate for associated inflammatory bowel disease. Treatment: There is no cure for PSC, and treatment primarily focuses on managing symptoms, slowing disease progression, and preventing complications. Medications may be prescribed to relieve itching, manage inflammation, and address complications. In some cases, endoscopic or surgical procedures may be necessary to relieve bile duct blockages. Monitoring and Complications: Regular monitoring is crucial for individuals with PSC to assess disease progression, manage symptoms, and screen for complications such as liver cirrhosis, bile duct cancer, and other liver-related problems. Liver transplant may be considered for individuals with advanced PSC and severe liver damage or complications. PSC is a chronic condition that requires ongoing care and monitoring by healthcare providers specializing in gastroenterology or hepatology. Management often involves a multidisciplinary approach, including gastroenterologists, hepatologists, surgeons, and

4. other healthcare professionals, to address various aspects of the disease and optimize treatment strategies. While treatment can help manage symptoms and slow disease progression, PSC is associated with a risk of complications and may require vigilant long-term management to improve quality of life and reduce the risk of serious liver-related issues. Key Facts Primary Sclerosing Cholangitis Market Report: ● The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032). ● According to DelveInsight analysis, the United States accounted for the highest market size of $78 million, with significant market share of PSC in 2022 in the 7MM. The market size of the 7MM is anticipated to increase in the forecast period due to the expected launch of emerging therapy. ● Among EU4 and the UK, Germany, Italy, and the UK accounted for the highest market size with approximately 25% each of the total market size in the EU4 and the UK in the year 2022, whileSpainaccounted for the lowest market in the year 2022. ● As per DelveInsight estimates, the market size in Japan was approximately USD 4 million in 2022. These numbers are expected to increase during the forecasted period. Primary Sclerosing Cholangitis Epidemiology Insights: ● In 2022, there were about 9,171 diagnosed asymptomatic cases of PSC and 11,038 diagnosed symptomatic cases PSC, in the EU4 and the UK. ● As per DelveInsight’s analysts, in Japan, there were approximately 2,443 diagnosed prevalent cases of PSC in the year 2022 accounting for nearly 5% of the total diagnosed prevalent cases of PSC in the 7MM. Primary Sclerosing Cholangitis Epidemiology Segmentation: The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: • Total Prevalence of Primary Sclerosing Cholangitis

5. • Prevalent Cases of Primary Sclerosing Cholangitis by severity • Gender-specific Prevalence of Primary Sclerosing Cholangitis • Diagnosed Cases oF Primary Sclerosing Cholangitis For in-depth insights, access the full report @ Primary Sclerosing Cholangitis Market Outlook 2032 Related Reports: Primary Sclerosing Cholangitis Epidemiology Forecast Primary understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Sclerosing Cholangitis Epidemiology Forecast report delivers an in-depth Primary Sclerosing Cholangitis Pipeline Insight Primary Sclerosing Cholangitis Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. Healthcare Consulting and Market Research Services by DelveInsight Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services About DelveInsight: DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance. Connect with DelveInsight: LinkedIn | Facebook | Twitter Contact Us: Kritika Rehani

6. krehani@delveinsight.com +91-9650213330 www.delveinsight.com